Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
17/09/2025
Morgan Stanley upgraded Wanhua Chemical's rating to overweight, with a target price of 80 Chinese yuan.
Latest
1 m ago
Continuous innovation in the listing methods: the surge in the expansion of "A+H" dual listings.
4 m ago
New consumption "dressing up" paves the way for securitization, makeup industry chain companies flock to IPO.
6 m ago
Tencent Holdings: has entered into a subscription agreement with the underwriter for the issuance of bonds with a total principal amount of 9 billion yuan according to the plan.
6 m ago
Tencent Holdings announced on the Hong Kong Stock Exchange on September 16, 2025 that the company has entered into a subscription agreement with underwriters for the planned issuance of a total principal amount of 9 billion yuan in notes. After deducting underwriting fees, discounts, and commissions, it is estimated that the net proceeds from the issuance of the notes will be approximately 8.97 billion yuan. The company plans to use the net proceeds for general corporate purposes.
7 m ago
GlaxoSmithKline (GSK): Will invest $30 billion in research and manufacturing in the United States over the next five years.
See all latest